In Brief: Tri-Point Medical
This article was originally published in The Gray Sheet
Executive Summary
Tri-Point Medical: Inks supply and distribution agreement under which Johnson & Johnson's Ethicon subsidiary gains worldwide marketing rights to its Traumaseal topical, nonabsorbable wound-closure adhesive product. The device began U.S. clinical trials in January ("The Gray Sheet" Jan. 15, In Brief) and the company anticipates completion of the studies this summer. The Raleigh, North Carolina-based firm hopes to submit a premarket approval application by year end. The deal includes "an up-front payment" and "cash advances on future purchases and milestone payments" upon FDA approval, the firm states. Terms were not disclosed...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.